Pubmed ID: 28212658
Publication Date: 2017/02/17

c-Met expression and activity in urogenital cancers - novel aspects of signal transduction and medical implications.

C-Met is a receptor tyrosine kinase with multiple functions throughout embryonic development, organogenesis and wound healing and is expressed in various epithelia. The ligand of c-Met is Hepatocyte Growth Factor (HGF) which is secreted among others by mesenchymal stroma/stem (MSC) cells.Physiological c-Met functions are centred around processes that underly cellular motility and invasive growth. Aberrant c-Met expression and activity is observed in numerous cancers and makes major contributions to cell malignancy. Importantly, HGF/c-Met signaling is crucial in the context of communication between cancer cells and the the tumor stroma.Here, we review recent findings on roles of dysregulated c-Met in urogenital tumors such as cancers of the urinary bladder, prostate, and ovary. We put emphasis on novel aspects of cancer-associated c-Met expression regulation on both, HGF-dependent and HGF-independent non-canonical mechanisms. Moreover, this review focusses on c-Met-triggered signalling with potential relevance for urogenital oncogenesis, and on strategies to specifically inhibit c-Met activity.

Authors: Hass Ralf , Jennek Susanne , Yang Yuanyuan , Friedrich Karlheinz ,

Reference:

Related products :

Catalog number	Product name	Quantity
29-810	Rgs7 inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits thereby driving them into their inactive GDP-bound form. Activity on G (o)-alpha is specifically enhance	0.1 mg
AA0009	Signal transduction antibody array includes 165 highly specific and well-characterized antibodies in the signal transduction pathway.	2 Pieces/Box
29-812	Rgs1 inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits thereby driving them into their inactive GDP-bound form.	0.1 mg
31-065	RGS3 inhibits signal transduction by increasing the GTPASE activity of G protein alpha subunits thereby driving them into their inactive GDP-bound form.	0.1 mg
29-809	Rgs2 inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits thereby driving them into their inactive GDP-bound form. It may play a role in leukemogenesis.	0.1 mg